JD Health (6618.HK) 23Q1 - As Industry Beta Fades, the Expectation Reversal Has yet to Come
As industry beta brought by COVID-19 dividend fades away, JD Health's performance growth would slow down.The current business model cannot support high valuation, so the turning point has not yet come